Published in final edited form as:

Biochemistry. 2011 April 19; 50(15): 3240–3249. doi:10.1021/bi200094z.

Interactions between the Etoposide Derivative F14512 and Human Type II Topoisomerases: Implications for the C4 Spermine Moiety in Promoting Enzyme-mediated DNA Cleavage†

Amanda C. Gentry[‡], Steven L. Pitts[‡], Michael J. Jablonsky[§], Christian Bailly^{||}, David E. Graves[§], and Neil Osheroff^{‡,¶,*}

Departments of Biochemistry and Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama 35294, and Institut de Recherche Pierre Fabre, 31035 Toulouse cedex 1, France

Abstract

F14512 is a novel etoposide derivative that contains a spermine in place of the C4 glycosidic moiety. The drug was designed to exploit the polyamine transport system that is upregulated in some cancers. However, a preliminary study suggests that it is also a more efficacious topoisomerase II poison than etoposide [Barret et al. (2008) *Cancer Res* 68, 9845–9853]. Therefore, we undertook a more complete study of the actions of F14512 against human type II topoisomerases. As determined by saturation transfer difference [¹H]-NMR spectroscopy, contacts between F14512 and human topoisomerase II α in the binary enzyme-drug complex are similar to those of etoposide. Although the spermine of F14512 does not interact with the enzyme, it converts the drug to a DNA binder [Barret et al. (2008)]. Consequently, the influence of the C4 spermine on drug activity was assessed. F14512 is a highly active topoisomerase II poison and stimulates DNA cleavage mediated by human topoisomerase II α or topoisomerase II β . The drug is more potent and efficacious than etoposide or TOP-53, an etoposide derivative that contains a C4 aminoalkyl group that strengthens drug-enzyme binding. Unlike the other drugs, F14512 maintains robust activity in the absence of ATP. The enhanced activity of F14512 correlates with a tighter binding and an increased stability of the ternary topoisomerase II-drug- DNA complex. The spermine-drug core linkage is critical for these attributes. These findings demonstrate the utility of a C4 DNA binding group and provide a rational basis for the development of novel and more active etoposide-based topoisomerase II poisons.

Etoposide is a widely prescribed anticancer agent that is used as front line therapy to treat a variety of human malignancies (1–4). The drug is currently in its fourth decade of clinical use and kills cells by stabilizing covalent topoisomerase II-cleaved DNA complexes that are requisite intermediates in the catalytic cycle of the enzyme (1–8). These transient “cleavage complexes” are converted to permanent DNA strand breaks by collisions with polymerases and other DNA tracking systems, which in turn leads to the accumulation of chromosomal aberrations and triggers cell death pathways (4, 6–11). Because etoposide converts type II topoisomerases to cellular toxins, it is referred to as a topoisomerase II poison (4–8).

[†]This work was supported by National Institutes of Health research grant GM33944 (to N.O.) and the National Science Foundation Grant MCB-0334785 (to D.E.G.). A.C.G. was a trainee under grant T32 CA09582 from the National Institutes of Health.

^{*}To whom correspondence should be addressed: tel, 615-322-4338; fax, 615-343-1166; neil.osheroff@vanderbilt.edu.

[‡]Vanderbilt University School of Medicine, Department of Biochemistry.

[§]Vanderbilt University School of Medicine, Department of Medicine (Hematology/Oncology).

^{||}University of Alabama at Birmingham, Department of Chemistry.

[¶]Pierre Fabre, Institut de Recherche.

Although regimes that include etoposide generate successful outcomes against a range of cancers, the cytotoxic nature of the drug induces significant side effects, including cardiotoxicity, myelosuppression, and gastrointestinal toxicity (1, 2, 12, 13). Furthermore, ~2–3% of patients that are treated with etoposide go on to develop specific secondary leukemias that involve the mixed lineage leukemia (*MLL*) gene at chromosomal band 11q23 (4, 14–16). Since the toxic side effects of etoposide are predominantly mechanism-based (*i.e.*, result from the actions of the drug against topoisomerase II), they are difficult to eliminate. Etoposide and other anticancer drugs affect both isoforms of human topoisomerase II, topoisomerase II α and topoisomerase II β (5–8, 17). Evidence suggests that topoisomerase II β may play a more important role than topoisomerase II α in mediating off-target toxicities and generating leukemic chromosomal translocations (18–20).

One way to decrease the off-target toxicity of etoposide and related drugs is to increase their specificity for malignant tissues. To this point, the polyamine transport system is more active in proliferating cells than resting cells, and the uptake of polyamines by some cancer cells is even greater (21–24). Therefore, in an effort to enhance the uptake of etoposide by cancer cells, F14512 was developed (Figure 1) (25). This derivative replaces the carbohydrate moiety at the C4 position of etoposide, which does not interact with topoisomerase II in the binary enzymedrug complex (26, 27), with the polyamine spermine. The spermine moiety is conjugated to the etoposide core through a glycyl spacer and was selected for optimal activity among a large series of conjugates (25).

F14512 is taken up by mammalian cells through the polyamine transport system and, compared to etoposide, displays increased potency against most cancer cell lines (25). Furthermore, F14512 is more active than the parent compound against a mouse MX-1 human breast tumor xenograft model and displays a higher therapeutic index and lower systemic toxicity (25). The drug also displays high activity against a variety of other xenograph models, including solid tumors (28) and leukemia (29), and currently is in phase I clinical trials for the treatment of acute myeloid leukemia.

Although the spermine moiety originally was attached to F14512 in order to change the cellular uptake properties of etoposide, the inclusion of the polyamine had two additional effects (25). First, it altered the DNA binding properties of the compound. While etoposide displays little interaction with DNA (in the absence of topoisomerase II) (30, 31), F14512 is a DNA binder, most likely interacting with the double helix through the minor groove (25). Second, as determined by preliminary *in vitro* studies, F14512 appears to be a more efficacious topoisomerase II poison than etoposide (25).

Given the high activity of F14512 in preclinical cancer models, it is important to understand how the drug interacts with potential cellular targets. Therefore, the effects of the C4 spermine moiety on drug function against human type II topoisomerases were analyzed. Results indicate that the C4 polyamine increases the potency and efficacy of the drug against both isoforms of human topoisomerase II, but does not change the fundamental mechanism of etoposide action (*i.e.*, inhibition of DNA ligation). Rather, the linkage between the spermine and the drug core appears to enhance drug binding and the stability of etoposide in the ternary enzyme-drug-DNA complex.

EXPERIMENTAL PROCEDURES

Enzymes and Materials

Human topoisomerase II α and topoisomerase II β were expressed in *Saccharomyces cerevisiae* (32) and purified as described previously (33). Human topoisomerase I was purchased from Topogen. Negatively supercoiled pBR322 DNA was prepared from

Escherichia coli using a Plasmid Mega Kit (Qiagen) as described by the manufacturer. Positively supercoiled pBR322 DNA was prepared by incubating negatively supercoiled plasmid with *Archaeoglobus fulgidus* reverse gyrase as described by McClendon et al. (34). Positively and negatively supercoiled plasmids contained an equivalent number of superhelical twists, but were of opposite handedness. [γ - ^{32}P]ATP (~5000Ci/mmol) was obtained from NEN. Etoposide and ciprofloxacin were from Sigma. TOP-53 was a gift from Taiho Pharmaceuticals. F14512 (patent WO 2005/100363) was synthesized as described previously (25). 4'-Demethyl epipodophyllotoxin (DEPT)¹ was the gift of Dr. Norma Dunlap (Middle Tennessee State University). Etoposide, TOP-53, DEPT and F14512 were stored at 4 °C as 20 mM stock solutions in 100% DMSO. Ciprofloxacin was stored at -20 °C as a 40 mM stock solution in 0.1 N NaOH. All other chemicals were analytical reagent grade.

STD [^1H]-NMR Spectroscopy

NMR spectra were generated using conditions similar to those described previously (26, 27). All NMR experiments were performed at 283 K using a Bruker Avance 700 MHz spectrometer equipped with a 5 mm cryoprobe with z gradients. NMR buffers contained 10 mM sodium phosphate (pH 7.7), 250 mM KCl, 0.1 mM Na₂EDTA, and 5 mM MgCl₂. Samples (400 μL) contained 5 μM human topoisomerase II α and 500 μM F14512 and were maintained at 4 °C until data were collected. STD [^1H]-NMR experiments employed a pulse scheme similar to that reported by Mayer and Meyer (35). A 2 s saturation pulse was used for the saturation, with on- and off-resonance irradiation frequencies of 0.5 and -71 ppm, respectively. The water signal was suppressed using excitation sculpting with gradients. For each experiment (on- and off-resonance irradiation), 256 scans were collected with a 2 s recycle time. Difference spectra were prepared by subtracting the on-resonance spectrum from the offresonance spectrum. Signals resulting in the difference spectrum represent the NOE difference signals generated by the transfer of irradiation energy from the enzyme to the bound ligand. Ligand protons in close spatial proximity with the enzyme displayed larger NOE signals. Mapping of the NOE signals with their proton assignments on the ligand revealed the ligandbinding epitope to human topoisomerase II α . Spectra were processed using Bruker Topspin software.

Plasmid DNA Cleavage

DNA cleavage reactions were carried out using the procedure of Fortune and Osheroff (36). Topoisomerase II DNA cleavage assays contained 110 nM human topoisomerase II α or 220 nM human topoisomerase II β and 10 nM negatively or positively supercoiled pBR322 in a total of 20 μL of DNA cleavage buffer [10 mM Tris-HCl (pH 7.9), 5 mM MgCl₂, 100 mM KCl, 0.1 mM EDTA, and 2.5% (v/v) glycerol]. Assays were carried out in the absence of compound or in the presence of 0–100 μM etoposide, TOP-53, DEPT, spermine, or F14512, or in the presence of a 1:1 mixture of etoposide + spermine or DEPT + spermine. Some reactions were carried out in the presence of 1mM ATP or APP(NH)P. Competition experiments also contained 0–1000 μM ciprofloxacin. Reaction mixtures were incubated at 37 °C for 6 min and enzyme-DNA cleavage complexes were trapped by the addition of 2 μL of 5% SDS followed by 2 μL of 250 mM EDTA (pH 8.0). Proteinase K (2 μL of a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 30 min to digest the enzyme. Samples were mixed with 2 μL of agarose gel loading buffer [60% sucrose in 10 mM Tris-HCl (pH 7.9)], heated at 45 °C for 5 min, and subjected to electrophoresis in 1% agarose gels in 40 mM Trisacetate (pH 8.3) and 2 mM EDTA containing 0.5 $\mu\text{g/mL}$ ethidium bromide. DNA bands were visualized with long-range ultraviolet light and

¹Abbreviations: DEPT, 4'-demethyl epipodophyllotoxin; STD, saturation transfer difference; NOE, nuclear Overhauser enhancement

quantified using an Alpha Innotech digital imaging system. DNA cleavage was monitored by the conversion of supercoiled plasmid DNA to linear molecules.

DNA Cleavage Site Utilization

DNA cleavage sites were mapped using a modification (37) of the procedure of O'Reilly and Kreuzer (38). The pBR322 DNA substrate was linearized by treatment with *Hind*III. Terminal 5'-phosphates were removed by treatment with calf intestinal alkaline phosphatase and replaced with [³²P]phosphate using T4 polynucleotide kinase and [γ -³²P]ATP. The DNA was treated with *Eco*RI, and the 4332 bp singly-end-labeled fragment was purified from the small *Eco*RI-*Hind*III fragment by passage through a CHROMA SPIN+TE-100 column (Clontech). Reaction mixtures contained 4 nM labeled pBR322 DNA substrate and 110 nM human topoisomerase II α or topoisomerase II β in 20 μ L of DNA cleavage buffer supplemented with 0.5 mM ATP in the absence or presence of 5–10 μ M etoposide, 5–10 μ M TOP-53, or 1–5 μ M F14512. Reaction mixtures were incubated at 37 °C for 6 min and enzyme-DNA cleavage complexes were trapped by the addition of 2 μ L of 5% SDS followed by 2 μ L of 250 mM EDTA (pH 8.0). Proteinase K (2 μ L of a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 30 min to digest the enzyme. DNA products were ethanol precipitated and resuspended in 6 μ L of 40% formamide, 10 mM NaOH, 0.02% xylene cyanol FF, and 0.02% bromophenol blue. Samples were subjected to electrophoresis in denaturing 6% polyacrylamide sequencing gels. Gels were dried in vacuo, and DNA cleavage products were visualized with a Bio-Rad Molecular Imager FX.

DNA Ligation

DNA ligation mediated by topoisomerase II α was monitored according to the procedure of Byl et al. (39). DNA cleavage/ligation equilibria were established for 6 min at 37 °C in the absence or presence of 50 μ M etoposide, 50 μ M TOP-53, or 10 μ M F14512. Ligation was initiated by shifting samples from 37 to 0 °C. Reactions were stopped at time points ranging from 0–30 s by the addition of 2 μ L of 5% SDS followed by 2 μ L of 250 mM EDTA (pH 8.0). Samples were mixed with 2 μ L of agarose gel loading buffer and processed and analyzed as described under plasmid DNA cleavage. Linear DNA cleavage product at time zero was set to 100% and DNA ligation was monitored by the loss of linear DNA.

DNA Intercalation

DNA intercalation was monitored as described previously (40). Intercalation reaction mixtures contained 20 nM topoisomerase I, 5 nM pBR322 DNA, and 0–100 μ M F14512, 20 μ M ethidium bromide, or 50 μ M etoposide, in a total of 20 μ L of 50 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 50 mM KCl, 10 mM MgCl₂, and 0.5 mM DTT. Mixtures were incubated at 37 °C for 10 min, extracted with a phenol/chloroform/isoamyl alcohol mixture (25:24:1), and added to 3 μ L of 0.77% SDS and 77 mM EDTA (pH 8.0). Samples were mixed with 2 μ L of agarose gel loading buffer, heated at 45 °C for 5 min, and subjected to electrophoresis in a 1% agarose gel in 100 mM Tris-borate (pH 8.3) and 2 mM EDTA. Gels were stained with 1 μ g/mL ethidium bromide, and DNA bands were visualized as described for plasmid DNA cleavage.

Persistence of Ternary Topoisomerase II α -Drug-DNA Complexes

The persistence of topoisomerase II α -drug-DNA complexes was determined using a modification of the procedure of Bandele et al. (41). Initial reactions contained 50 nM DNA, 550 nM topoisomerase II α and 100 μ M etoposide or 10 μ M F14512 in a total of 20 μ L of DNA cleavage buffer. Reactions were incubated at 37 °C for 6 min and then diluted 20-fold with DNA cleavage buffer at 37 °C. Samples (20 μ L) were removed at times ranging from 0–150 min, and DNA cleavage was stopped with 2 μ L of 5% SDS. Samples were processed

as described above for plasmid cleavage assays. Levels of DNA cleavage were set to 100% at time zero, and the persistence of cleavage complexes was determined by the decay of linear reaction product over time.

RESULTS AND DISCUSSION

Interactions between F14512 and Human Topoisomerase II α

Previous studies indicate that interactions between topoisomerase II and etoposide are critical for drug activity and mediate the entry of etoposide into the ternary enzyme-drug-DNA complex (26, 27, 42, 43). Furthermore, drug contacts in the binary topoisomerase II-drug complex, including the C15 geminal protons of the A-ring, the C5 and C8 protons of the B-ring, and the C2' and C6' protons and the 3'- and 5'-methoxyl protons of the pendant E-ring (as determined by STD [¹H]-NMR spectroscopy) have predictive value for the actions of etoposide within the ternary drug-enzyme-DNA complex (26, 27, 44, 45). Indeed, alterations of A-ring and E-ring substituents dramatically decrease the efficacy of etoposide against topoisomerase II. In contrast, removal of the C4 glycosidic group (which generates DEPT, Figure 1) has relatively little effect on the ability of the drug to poison topoisomerase II.

F14512 shares an identical core (rings A–E) with etoposide but contains a spermine group in place of the glycosidic moiety at the C4 position (Figure 1). Therefore, as a first step in characterizing the activity of the compound against human type II topoisomerases, we used STD [¹H]-NMR spectroscopy to define the substituents on F14512 that contact topoisomerase II α in the binary enzyme-drug complex. With the exception of one additional contact with the enzyme (the C4 proton of the C-ring) the substituents on the drug core that contacted topoisomerase II α in the binary complex were identical to those previously described for etoposide (Table 1 and Figure 2) (26, 27). It is notable that no significant nuclear Overhauser enhancement (NOE) signals were observed for any of the protons of the spermine moiety of F14512. This result suggests that there is limited interaction, if any, between this portion of F14512 and the enzyme.

Although the C4 substituents of etoposide and F14512 do not interact with topoisomerase II α , it is possible to substitute this position with a protein-binding group. To this point, TOP-53 is a derivative of etoposide that contains a C4 aminoalkyl side chain (Figure 1) (46). In contrast to results with etoposide or F14512, every proton associated with this side chain of TOP-53 contacts topoisomerase II α in the binary complex (26). Furthermore, the presence of the aminoalkyl group increases the binding affinity of TOP-53 for topoisomerase II and significantly enhances the potency and efficacy of the drug against the type II enzyme (Figure 3) (26, 47).

In contrast to the C4 aminoalkyl side chain of TOP-53, the spermine moiety of F14512 interacts with DNA and converts the drug to a DNA binder (25). Taken together, these results suggest that the C4 substituents of compounds in the etoposide family have the potential to influence drug activity by two distinct mechanisms: enhanced binding to the enzyme or enhanced binding to DNA. Consequently, we wanted to more fully investigate the influence of the C4 spermine on F14512 activity.

F14512 Poisons Human Type II Topoisomerases

Preliminary results using human topoisomerase II α suggest that F14512 is a more efficacious poison than etoposide (25). Therefore, to examine the activity of F14512 in greater detail, the effects of the drug on DNA cleavage mediated by human type II topoisomerases were compared to those of etoposide and TOP-53. As seen in Figure 3, F14512 was several-fold more potent and more efficacious than either drug. Similar results

were observed with topoisomerase II α (*left panel*) and topoisomerase II β (*right panel*). In all cases, F14512 generated the highest levels of double-stranded, singlestranded, and total topoisomerase II-mediated DNA strand breaks. These results demonstrate that the inclusion of the DNA-binding C4 spermine in F14512 has a marked effect on drug activity. Furthermore, this effect is even greater than that generated by the enzyme-binding aminoalkyl group in TOP-53.

It is notable that F14512 is considerably more active against topoisomerase II α than topoisomerase II β . Comparable or higher levels of DNA scission were observed with the α isoform, despite the fact that the enzyme concentration employed was only one half that used in topoisomerase II β assays (Figure 3). Furthermore, at concentrations of F14512 that exceeded 15 μ M, multiple cleavage events per plasmid were observed with topoisomerase II α , such that it became impossible to accurately quantify levels of double-stranded DNA breaks.

Eukaryotic type II topoisomerases are homodimeric proteins (48–50). Each protomer active site of the enzyme cuts one strand of the DNA to generate a double-stranded break (51). The two enzyme protomers are not fully coordinated and, as a result, also create single-stranded breaks (52–54). The double-stranded:single-stranded cleavage ratio differs between drug classes, with etoposide yielding a relatively low ratio (~0.5:1 at 10 μ M drug) with topoisomerase II α (Figure 3, *lower left panel inset*) (52). Of the three drugs, F14512 induced the highest ratio of doublestranded: single-stranded breaks (~1:1 at 10 μ M drug with topoisomerase II α) (Figure 3, *lower left panel inset*).

Type II topoisomerases require ATP binding and hydrolysis for overall catalytic activity (55–57). Several studies have demonstrated that etoposide displays maximal activity only in the presence of a high-energy cofactor (58), although the mechanistic basis for this property is not understood. As seen in Figure 4, levels of topoisomerase II α -mediated DNA cleavage induced by etoposide and TOP-53 drop ~3- and ~2-fold, respectively, in the absence of ATP. In contrast, F14512 was far better at maintaining activity in the absence of ATP, with cleavage levels declining only 15% in assays that lacked the cofactor.

Drug-induced DNA cleavage also was assessed in the presence of the non-hydrolyzable ATP analog APP(NH)P. This analog allows type II topoisomerases to go through one round of DNA strand passage, but does not support enzyme turnover (56). Once again, the highest levels of DNA cleavage were observed in the presence of F14512 as compared to etoposide or TOP-53. Furthermore, the spermine-linked drug displayed the least dependence (~2-fold) on APP(NH)P for its enhanced activity as compared to the other drugs (~5- to 6-fold higher levels of cleavage in the presence of the non-hydrolyzable ATP analog) (Figure 4).

Because the C4 spermine moiety of F14512 interacts with DNA, it is possible that it alters the cleavage site specificity of topoisomerase II α and topoisomerase II β . In order to assess this issue, we determined the DNA sites that are cleaved by the human enzymes in the presence of etoposide, TOP-53, and F14512 (Figure 5). A similar (but not identical) array of sites was cleaved with all three drugs. This finding suggests that the addition of the spermine moiety to the etoposide core does not promote site-specific DNA interactions and is consistent with the general DNA properties of the polyamine. A similar conclusion was reached in an earlier study that examined a more limited sampling of DNA sites cleaved by topoisomerase II α (25).

Etoposide increases levels of covalent topoisomerase II-DNA cleavage complexes by inhibiting the ability of the enzyme to ligate DNA breaks (59, 60). Therefore, a ligation assay was employed to determine whether the inclusion of the spermine moiety alters the mechanistic basis for drug action. As seen in Figure 6, etoposide, TOP-53, and F14512 are

all potent inhibitors of DNA ligation mediated by human topoisomerase II α . Given the strong inhibition, it is not possible to determine whether the higher levels of DNA cleavage generated by F14512 reflect an enhanced inhibition of the ligation reaction.

F14512–DNA Interactions are Non-intercalative

It has long been known that etoposide binds weakly if at all to DNA in the absence of topoisomerase II (30, 31). In contrast, a previous study that assessed changes in DNA melting temperatures, as well as the ultraviolet and circular dichroism spectra of DNA, concluded that F14512 is a DNA binding drug (25). While changes in circular dichroism suggest that F14512 binds to the double helix through the minor groove, the study did not determine the DNA binding mode of the drug (25).

Another study found that attachment of spermine to anthracene (which is a poor DNA intercalator) generated an intercalative drug (61). Therefore, two experiments were carried out to determine whether F14512 intercalates into DNA. The first experiment utilized a topoisomerase I-DNA relaxation assay to monitor intercalation. This assay is based on the fact that intercalative agents induce constrained negative supercoils and compensatory unconstrained positive superhelical twists in covalently closed circular DNA (17, 40, 62). Therefore, as the concentration of an intercalative compound increases, a plasmid that is negatively supercoiled or relaxed (i.e., contains no superhelical twists) appears to become positively supercoiled. Treatment of an intercalated plasmid with topoisomerase I removes the unconstrained positive DNA superhelical twists. Subsequent extraction of the compound allows the local drug-induced unwinding to redistribute in a global manner and manifest itself as a net negative supercoiling of the plasmid. Thus, in the presence of an intercalative agent, topoisomerase treatment converts relaxed plasmids to negatively supercoiled molecules. As seen in Figure 7 (*top*), F14512 displayed no ability to intercalate over the concentration range that promoted topoisomerase II-mediated DNA cleavage (0–100 μ M).

The second experiment takes advantage of the finding that topoisomerase II α maintains 2– to 3-fold higher levels of DNA cleavage complexes with negatively supercoiled DNA as compared to positively supercoiled molecules (34, 63). While this relationship is maintained over a broad concentration range in the presence of non-intercalative topoisomerase II poisons, it does not hold when intercalative drugs are utilized (63). In this latter case, cleavage levels of negatively supercoiled plasmids relative to positively supercoiled substrates drop as the concentration of intercalator increases. Over the concentration range of F14512 examined, the percent cleavage of negatively supercoiled plasmids remained 2– to 3-fold higher than that seen with the corresponding positively supercoiled substrate (Figure 7, *bottom*). These findings provide strong evidence that F14512 does not utilize an intercalative mode to bind DNA.

Enhanced Stability and Tighter Drug Binding in the Ternary Topoisomerase II α -F14512-DNA Complex

F14512 displays similar contacts as etoposide with human topoisomerase II α in the binary enzyme-drug complex (see Table 1 and Figure 2), but has additional interactions with the double helix in the binary DNA-drug complex (25). Since F14512 is a more potent topoisomerase II poison than etoposide, we wanted to see if these DNA interactions contribute to an enhanced stability or a tighter drug binding of the spermine-linked drug in the ternary topoisomerase II α -drug-DNA complex. Two approaches were used to address these issues. In the first, the persistence of DNA cleavage complexes (41) established in the presence of F14512 or etoposide was determined. This was accomplished by establishing DNA cleavage-ligation equilibria in the presence of 10 μ M F14512 or 100 μ M etoposide, diluting reaction mixtures 20– fold, and monitoring the decay of cleavage complexes over

time. As seen in Figure 8, cleavage complexes formed in the presence of F14512 persisted 5– to 10–fold longer than equivalent complexes induced by etoposide. This suggests that F14512 forms a more stable ternary complex than etoposide.

In the second approach, the ability of the quinolone ciprofloxacin to compete with F14512 or etoposide for binding in the ternary complex was determined. Ciprofloxacin is an antibacterial topoisomerase II poison (64, 65) that displays little ability to stimulate DNA cleavage mediated by the eukaryotic type II enzyme (66). However, the quinolone interacts with eukaryotic topoisomerase II and shares a binding site with anticancer drugs (66). Thus, it can inhibit the ability of these drugs to enhance DNA scission (66).

As seen in Figure 9, ciprofloxacin competed with both F14512 and etoposide, but the ciprofloxacin:F14512 ratio required to decrease DNA cleavage was 5– to 10–fold higher than seen with etoposide. These experiments indicate that F14512 binds more tightly than etoposide in the ternary enzyme-drug-DNA complex. The enhanced stability of cleavage complexes formed in the presence of F14512 and the tighter drug binding provide a probable basis for the greater efficacy and potency of F14512 compared to etoposide.

Importance of the Spermine-Drug Linkage to the Enhanced Activity of F14512 Against Topoisomerase II α

Experiments in the previous section suggest that the spermine-mediated binding of F14512 to DNA is responsible for the enhanced activity of the drug. However, spermine-DNA interactions also neutralize nucleic acid charge and allow condensation of the double helix (67–69). Furthermore, polyamines such as spermine and spermidine can alter interactions between type II topoisomerases and DNA and are used routinely as DNA condensation agents to convert intramolecular to intermolecular DNA strand passage reactions (*i.e.*, DNA relaxation to catenation) (70).

Therefore, to determine whether the spermine moiety alters F14512 activity by a specific effect on drug interactions in the ternary complex or by a general effect on DNA charge/structure, we characterized the importance of the spermine-drug linkage to the activity of F14512. As a first step, drug binding in the ternary enzyme-drug-DNA complex was assessed when the complex was formed in the simultaneous presence of the unlinked etoposide core (*i.e.*, DEPT, see Figure 1) and spermine. As assessed by the ciprofloxacin competition assay (Figure 9), the affinity of a 1:1 DEPT:spermine mixture for the topoisomerase II α -DNA complex was similar to that of etoposide and was ~10–fold lower than that of F14512. This finding indicates that the drug-spermine linkage is critical for the tighter binding of F14512 in the ternary complex.

The effects of the drug-spermine linkage on the activity of F14512 also were determined. As seen in Figure 10, spermine (up to 100 μ M) had little influence on levels of DNA cleavage mediated by human topoisomerase II α (71). Moreover, DNA cleavage enhancement observed in the presence of a 1:1 DEPT:spermine mixture was comparable to that of the drug core in the absence of the polyamine. A similar result was seen comparing a 1:1 etoposide:spermine mixture to the activity of etoposide alone. Taken together, these results provide strong evidence that, in the concentration ranges examined, spermine does not enhance topoisomerase II-mediated DNA cleavage by a general effect on DNA charge or structure. Furthermore, the drug-spermine linkage is critical for the high activity of F14512.

In conclusion, F14512 is a novel etoposide derivative that contains a spermine group in place of the C4 glycosidic moiety (25). The presence of the spermine enhances the selectivity of the drug in cancers that overexpress an active polyamine transport system (25) (28) (29). In addition, F14512 is a more potent and efficacious topoisomerase II poison than

etoposide, and this enhanced activity correlates with tighter drug binding and an increased stability of the ternary topoisomerase II-drug-DNA complex. The linkage between the drug core and spermine, which converts etoposide to a DNA binder (25), is critical for the enhanced activity of F14512. While the A-, B-, and E-ring stabilize drug binding through protein interactions, we suggest that polyamine-DNA interactions provide a second anchor for the drug in the ternary complex.

The present findings highlight the utility of a C4 DNA binding group and provide a rational basis for the development of novel and more active etoposide-based topoisomerase II poisons. Finally, the dual function of the C4 spermine moiety (*i.e.*, enhanced cellular uptake in cancers with active polyamine transport and greater activity against topoisomerase II) supports the ongoing clinical development of F14512.

Acknowledgments

We are grateful to Adam C. Ketron and Katie J. Aldred for critical reading of the manuscript. We also wish to thank Dr. Clemens Anklin (Bruker) for his invaluable assistance with developing the protocols for the [^1H] STD-NMR spectroscopy. The contributions of the CROE/IRPF members to the synthesis and research on F14512 also are acknowledged.

References

1. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer*. 1998; 34:1514–1521. [PubMed: 9893622]
2. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. *Biochim Biophys Acta*. 1998; 1400:173–184. [PubMed: 9748560]
3. Holden JA. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. *Curr Med Chem Anti-Cancer Agents*. 2001; 1:1–25.
4. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. *Curr Med Chem Anti-Cancer Agents*. 2005; 5:363–372.
5. Pommier Y, Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. *Curr Med Chem Anti-Cancer Agents*. 2005; 5:421–429.
6. McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity and cancer. *Mut Res*. 2007; 623:83–97. [PubMed: 17681352]
7. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. *Nucleic Acids Res*. 2009; 37:738–748. [PubMed: 19042970]
8. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer*. 2009; 9:338–350. [PubMed: 19377506]
9. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. *Biochim Biophys Acta*. 1998; 1400:213–222. [PubMed: 9748584]
10. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. *Biochim Biophys Acta*. 1998; 1400:195–211. [PubMed: 9748575]
11. Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. *Curr Med Chem Anti-Cancer Agents*. 2003; 3:271–290.
12. Seiter K. Toxicity of the topoisomerase II inhibitors. *Expert Opin Drug Saf*. 2005; 4:219–234. [PubMed: 15794715]
13. Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. *Pharmacotherapy*. 1984; 4:61–73. [PubMed: 6326063]
14. DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. *Ann Intern Med*. 1989; 110:740–742. [PubMed: 2648930]
15. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. *Med Pediatr Oncol*. 2001; 36:525–535. [PubMed: 11340607]

16. Felix CA, Kolaris CP, Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. *DNA Repair (Amst)*. 2006; 5:1093–1108. [PubMed: 16857431]
17. McClendon AK, Osheroff N. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. *Biochemistry*. 2006; 45:3040–3050. [PubMed: 16503659]
18. Sehested M, Holm B, Jensen PB. Dexrazoxane for protection against cardiotoxic effects of anthracyclines. *J Clin Oncol*. 1996; 14:2884. [PubMed: 8874349]
19. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. *Proc Natl Acad Sci USA*. 2007; 104:11014–11019. [PubMed: 17578914]
20. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase II β mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Res*. 2007; 67:8839–8846. [PubMed: 17875725]
21. Bachrach U, Seiler N. Formation of acetylpolymamines and putrescine from spermidine by normal and transformed chick embryo fibroblasts. *Cancer Res*. 1981; 41:1205–1208. [PubMed: 6257381]
22. Chen KY, Liu AY. Differences in polyamine metabolism of the undifferentiated and differentiated neuroblastoma cells. Metabolic labeling of an 18,000- M(r) protein by [14C]putrescine and the conversion of putrescine to GABA. *FEBS Lett*. 1981; 134:71–74. [PubMed: 9222327]
23. Cullis PM, Green RE, Merson-Davies L, Travis N. Probing the mechanism of transport and compartmentalisation of polyamines in mammalian cells. *Chem Biol*. 1999; 6:717–729. [PubMed: 10508681]
24. Phanstiel O, Kaur N, Delcros JG. Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. *Amino Acids*. 2007; 33:305–313. [PubMed: 17410331]
25. Barret JM, Kruczynski A, Vispe S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. *Cancer Res*. 2008; 68:9845–9853. [PubMed: 19047165]
26. Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N, Graves DE. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. *Biochemistry*. 2007; 46:8217–8225. [PubMed: 17580961]
27. Bender RP, Jablonksy MJ, Shadid M, Romaine I, Dunlap N, Anklin C, Graves DE, Osheroff N. Substituents on etoposide that interact with human topoisomerase II α in the binary enzyme-drug complex: contributions to etoposide binding and activity. *Biochemistry*. 2008; 47:4501–4509. [PubMed: 18355043]
28. Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. *Invest New Drugs*. 2009; 29:9–21. [PubMed: 19777159]
29. Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M, Vispe S, Breand S, Guilbaud N, Barret JM, Bailly C. A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. *Leuk Res*. 2008; 34:1383–1389. [PubMed: 20096930]
30. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. *Cancer Res*. 1984; 44:5857–5860. [PubMed: 6094001]
31. Chow KC, Macdonald TL, Ross WE. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. *Mol Pharmacol*. 1988; 34:467–473. [PubMed: 2845248]
32. Worland ST, Wang JC. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast *Saccharomyces cerevisiae*. *J Biol Chem*. 1989; 264:4412–4416. [PubMed: 2538443]

33. Kingma PS, Greider CA, Osheroff N. Spontaneous DNA lesions poison human topoisomerase II α and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. *Biochemistry*. 1997; 36:5934–5939. [PubMed: 9166762]
34. McClendon AK, Rodriguez AC, Osheroff N. Human topoisomerase II α rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks. *J Biol Chem*. 2005; 280:39337–39345. [PubMed: 16188892]
35. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. *J Am Chem Soc*. 2001; 123:6108–6117. [PubMed: 11414845]
36. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase II α by blocking DNA cleavage. *J Biol Chem*. 1998; 273:17643–17650. [PubMed: 9651360]
37. Baldwin EL, Byl JA, Osheroff N. Cobalt enhances DNA cleavage mediated by human topoisomerase II α in vitro and in cultured cells. *Biochemistry*. 2004; 43:728–735. [PubMed: 14730977]
38. O'Reilly EK, Kreuzer KN. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. *Biochemistry*. 2002; 41:7989–7997. [PubMed: 12069589]
39. Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. *Biochemistry*. 1999; 38:15573–15579. [PubMed: 10569941]
40. Fortune JM, Velea L, Graves DE, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. *Biochemistry*. 1999; 38:15580–15586. [PubMed: 10569942]
41. Bandele OJ, Osheroff N. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. *Biochemistry*. 2008; 47:11900–11908. [PubMed: 18922022]
42. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N. Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. *J Biol Chem*. 1996; 271:29238–29244. [PubMed: 8910583]
43. Kingma PS, Burden DA, Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. *Biochemistry*. 1999; 38:3457–3461. [PubMed: 10090731]
44. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16–213 and VM26: a quantitative structure-activity relationship. *Biochemistry*. 1984; 23:1183–1188. [PubMed: 6712942]
45. Long BH, Casazza AM. Structure-activity relationships of VP-16 analogues. *Cancer Chemother Pharmacol*. 1994; 34(Suppl):S26–31. [PubMed: 8070024]
46. Kitamura R, Bandoh T, Tsuda M, Satoh T. Determination of a new podophyllotoxin derivative, TOP-53, and its metabolite in rat plasma and urine by highperformance liquid chromatography with electrochemical detection. *J Chromatogr B: Biomed Sci Appl*. 1997; 690:283–288. [PubMed: 9106054]
47. Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. *Biochemistry*. 2001; 40:712–718. [PubMed: 11170388]
48. Sander M, Hsieh T. Double strand DNA cleavage by type II DNA topoisomerase from *Drosophila melanogaster*. *J Biol Chem*. 1983; 258:8421–8428. [PubMed: 6305984]
49. Shelton ER, Osheroff N, Brutlag DL. DNA topoisomerase II from *Drosophila melanogaster*. Purification and physical characterization. *J Biol Chem*. 1983; 258:9530–9535. [PubMed: 6308010]
50. Halligan BD, Edwards KA, Liu LF. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. *J Biol Chem*. 1985; 260:2475–2482. [PubMed: 2982821]
51. Zechiedrich EL, Christiansen K, Andersen AH, Westergaard O, Osheroff N. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. *Biochemistry*. 1989; 28:6229–6236. [PubMed: 2551367]

52. Bromberg KD, Burgin AB, Osheroff N. A two-drug model for etoposide action against human topoisomerase II α . *J Biol Chem*. 2003; 278:7406–7412. [PubMed: 12473657]
53. Deweese JE, Burgin AB, Osheroff N. Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase II α . *Biochemistry*. 2008; 47:4129–4140. [PubMed: 18318502]
54. Deweese JE, Osheroff N. Coordinating the two protomer active sites of human topoisomerase II α : nicks as topoisomerase II poisons. *Biochemistry*. 2009; 48:1439–1441. [PubMed: 19166355]
55. Osheroff N, Shelton ER, Brutlag DL. DNA topoisomerase II from *Drosophila melanogaster*. Relaxation of supercoiled DNA. *J Biol Chem*. 1983; 258:9536–9543. [PubMed: 6308011]
56. Osheroff N. Eukaryotic topoisomerase II. Characterization of enzyme turnover. *J Biol Chem*. 1986; 261:9944–9950. [PubMed: 3015913]
57. Lindsley JE, Wang JC. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. *J Biol Chem*. 1993; 268:8096–8104. [PubMed: 8385137]
58. Wang H, Mao Y, Zhou N, Hu T, Hsieh TS, Liu LF. ATP-bound topoisomerase II as a target for antitumor drugs. *J Biol Chem*. 2001; 276:15990–15995. [PubMed: 11278845]
59. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. *Biochemistry*. 1989; 28:6157–6160. [PubMed: 2551366]
60. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strandpassage DNA cleavage/religation equilibrium of topoisomerase II. *Biochemistry*. 1991; 30:1807–1813. [PubMed: 1847075]
61. Rodger A, Taylor S, Adlam G, Blagbrough IS, Haworth IS. Multiple DNA binding modes of anthracene-9-carbonyl-N1-spermine. *Bioorg Med Chem*. 1995; 3:861–872. [PubMed: 7582962]
62. Pommier Y, Covey JM, Kerrigan D, Markovits J, Pham R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. *Nucleic Acids Res*. 1987; 15:6713–6731. [PubMed: 2819825]
63. McClendon AK, Gentry AC, Dickey JS, Brinch M, Bendson S, Andersen AH, Osheroff N. Bimodal recognition of DNA geometry by human topoisomerase II α : preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. *Biochemistry*. 2008; 47:13169–13178. [PubMed: 19053267]
64. Anderson VE, Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr Hyde. *Curr Pharm Des*. 2001; 7:337–353. [PubMed: 11254893]
65. Drlaca K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. Quinolones: action and resistance updated. *Curr Top Med Chem*. 2009; 9:981–998. [PubMed: 19747119]
66. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. *Antimicrob Agents Chemother*. 1993; 37:2179–2186. [PubMed: 8257142]
67. Lerman LS. A transition to a compact form of DNA in polymer solutions. *Proc Natl Acad Sci USA*. 1971; 68:1886–1890. [PubMed: 5288774]
68. Gosule LC, Schellman JA. Compact form of DNA induced by spermidine. *Nature*. 1976; 259:333–335. [PubMed: 1250371]
69. Vijayanathan V, Thomas T, Shirahata A, Thomas TJ. DNA condensation by polyamines: a laser light scattering study of structural effects. *Biochemistry*. 2001; 40:13644–13651. [PubMed: 11695913]
70. Marini JC, Miller KG, Englund PT. Decatenation of kinetoplast DNA by topoisomerases. *J Biol Chem*. 1980; 255:4976–4979. [PubMed: 6246090]
71. Pommier Y, Kerrigan D, Kohn K. Topological complexes between DNA and topoisomerase II and effects of polyamines. *Biochemistry*. 1989; 28:995–1002. [PubMed: 2540827]

Figure 1.

Structure of etoposide and derivatives. The spermine moiety at the C4 position of F14512 is indicated by the box. Asterisks mark protons that interact with topoisomerase II in the binary enzyme-drug complex as determined by STD [^1H]-NMR spectroscopy (26, 27) (see Figure 2 and Table 1).

Figure 2. Interaction of F14512 with human topoisomerase II α s determined by STD [1H]-NMR spectroscopy. Difference (top) and reference (off-resonance, bottom) spectra are shown. Spectra are representative of at least two independent experiments.

Figure 3.

F14512 is a potent topoisomerase II poison. The effects of etoposide, TOP-53, and F14512 on the cleavage of negatively supercoiled pBR322 plasmid DNA by human topoisomerase II α (left panels) and topoisomerase II β (right panels) were determined. The percentage of double-stranded (top panels), single-stranded (middle panels), and total DNA cleavage complexes (bottom panels) is shown. Error bars represent the standard deviation of 3 independent experiments. The inset in the left middle panel shows an agarose gel of topoisomerase II α -mediated cleavage of negatively supercoiled pBR322 plasmid DNA in the absence of drug (α) or in the presence of 15 μ M etoposide (E), TOP-53 (T), or F14512 (F). A DNA standard (D) also is shown. The positions of supercoiled (form I, FI), nicked circular (form II, FII), and linear (form III, FIII) molecules are indicated. The inset in the bottom left panel shows the ratio of double-stranded:single-stranded (DS/SS) breaks generated by topoisomerase II α in the presence of 10 μ M etoposide, TOP-53, or F14512.

Figure 4. Effects of ATP on drug-stimulated DNA cleavage mediated by human topoisomerase II α . Assays were carried out in the absence of ATP (closed bars) or in the presence of 1 mM ATP (open bars) or the non-hydrolyzable ATP analog APP(NH)P (gray bars). Reactions contained no drug (ND) or 5 μ M etoposide, TOP-53, or F14512. Error bars represent the standard deviation of 3 independent experiments.

Figure 5. Effects of etoposide derivatives on sites of DNA cleavage mediated by human topoisomerase II α (left) and topoisomerase II β (right). An autoradiogram of a polyacrylamide gel is shown. DNA cleavage reactions were carried out in the absence of drug (TII), or in the presence of the indicated concentrations of F14512, TOP-53, or etoposide. A DNA standard (DNA) also is shown. Results are representative of 3 independent experiments.

Figure 6.

Effects of etoposide derivatives on DNA ligation mediated by human topoisomerase II α . Reactions were carried out in the absence of drug (open squares) or in the presence of 50 μ M etoposide (closed circles), 50 μ M TOP-53 (closed squares), or 10 μ M F14512 (open circles). Ligation is expressed as the percent loss of linear DNA, which was set to 100% at time zero. Error bars represent the standard deviation of 3 independent experiments.

Figure 7.

F14512 is not a DNA intercalator. The ability of F14512 to intercalate into negatively supercoiled pBR322 plasmid DNA was determined using a topoisomerase I relaxation assay (top). An agarose gel is shown. DNA relaxation was carried out in the absence of drugs (TI), or in the presence of 0–100 μM F14512, 20 μM ethidium bromide (EB), or 20 μM etoposide (Etop). A DNA standard (DNA) also is shown. The gel is representative of three independent experiments. The bottom panel shows the effects of F14512 on the ability of human topoisomerase II α to cleave negatively (open circles) and positively (closed circles) supercoiled pBR322 plasmid molecules. Error bars represent the standard deviation of 3 independent experiments.

Figure 8.

Effects of etoposide derivatives on the persistence of ternary topoisomerase II α -drug- DNA cleavage complexes. Assays were carried out in the presence of etoposide (100 μ M) or F14512 (10 μ M) and negatively supercoiled pBR322 plasmid DNA. After initial reaction mixtures attained DNA cleavage-ligation equilibria, they were diluted 20-fold with DNA cleavage buffer. The persistence of cleavage complexes was assessed by monitoring the loss of double-stranded DNA breaks (linear product) over time. Cleavage at time zero was set to 100%. Error bars represent the standard error of 2 independent assays.

Figure 9.

F14512 binds more tightly than etoposide in the ternary topoisomerase II α -drug-DNA complex. A ciprofloxacin competition assay was employed. DNA cleavage complexes were established in the presence of etoposide (Etop), F14512, or a 1:1 mixture of DEPT + spermine and 0–1000 μ M ciprofloxacin (Cipro). Levels of DNA cleavage generated by human topoisomerase II α in the presence of ciprofloxacin alone were subtracted from those seen in the presence of etoposide derivatives + ciprofloxacin. Cleavage in the absence of ciprofloxacin was set to 100%, and results are presented as a ratio of ciprofloxacin concentration to etoposide derivative. Error bars represent the standard deviation of 3 independent experiments.

Figure 10.

The covalent linkage of the C4 spermine moiety to the etoposide core is necessary for the enhanced DNA cleavage seen in the presence of F14512. The ability of DEPT or a 1:1 mixture of DEPT + spermine (left panel), and etoposide (Etop) or a 1:1 mixture of etoposide + spermine (right panel) to enhance topoisomerase II α -mediated DNA cleavage is shown. Control experiments assessing the effects of spermine alone on the DNA cleavage activity of topoisomerase II α are shown in both panels. Error bars represent the standard deviation of 3 independent experiments.

Table 1

Drug Substituents that Interact with Human Topoisomerase II α in the Binary Enzyme- Drug Complex as Determined by STD [^1H]-NMR Spectroscopy^a

Etoposide		F14512	
Substituent Proton	Resonance	Substituent Proton	Resonance
1	4.39	1	4.52
2	3.33	2	3.18
3	2.83	3	2.99
4	4.82	4	5.00
5	6.70	5	6.61
8	6.32	8	6.32
11R, 11S	4.15, 4.20	11R, 11S	3.90, 4.30
15R, 15S	5.70	15R, 15S	5.70
2', 6'	6.18	2', 6'	6.17
3', 5'-OCH3	3.49	3', 5'-OCH3	3.49
1"	4.43	3"	3.78
2"	3.07	5"	2.97
3"	3.33	6"	2.05
4"	3.17	7"	3.04
5"	3.24	9", 12"	2.90
6", 6"	3.42, 4.01	10", 11"	1.72
7"	4.70	14", 16"	3.07
-CH3	1.10	15"	1.97

^aResonances that display nuclear Overhauser effects in STD [^1H]-NMR spectroscopy experiments along with the substituent protons that they represent are indicated in bold.